In vitro studies have confirmed that first generation HSP90 inhibitors (tanespimycin and alvespimycin) and second generation ones (onalespib), inhibit tumor cell growth and induce the degradation of client proteins, including AR-FL, AKT and GR (glucocorticoid receptor). This evidence concerns the gene HSP90AA1 and neoplasm.